26 September 2018 - It’s no secret that major biopharmaceutical companies have had designs on the China drug market as a source of revenue growth for drugs that have already been launched in the West. 

However, the unidirectional flow of new drug launches may start to change, albeit to a far lesser extent, as drug makers in China are planning to bring their home grown new drugs to the U.S. market. Chi-Med, a Chinese drug maker, recently made news by announcing its plans to develop its cancer drug, fruquintinib, in the U.S for an eventual commercial launch.

Fruquintinib, a VEGFR inhibitor, is nearing approval in China for colon cancer in patients who have already failed two other chemotherapies.

Read Forbes article